NCT06869941

Brief Summary

This study aims to understand how adipose tissue (fat) and the gut microbiota (the bacteria in the gut) may influence brain function and cognition. It has been observed that changes in adipose tissue in animals such as mice and Drosophila (a type of insect) affect memory and other brain functions. Additionally, it is believed that the gut microbiota also plays an important role in cognition. This study will explore how gene expression in adipose tissue, blood metabolites, and the gut microbiota are related to cognitive function, such as memory and thinking, in individuals with and without obesity. The investigation will also assess whether these factors can predict changes in the brain over time and how they influence sleep, physical activity, and blood sugar regulation. Advanced technologies will be used to analyze samples of tissue, blood, and microbiota, with the goal of identifying new mechanisms through which obesity affects the brain. This research may contribute to the development of new diagnostic and therapeutic strategies for cognitive problems in individuals with obesity.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
9mo left

Started Aug 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress51%
Aug 2025Jan 2027

First Submitted

Initial submission to the registry

March 5, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 11, 2025

Completed
5 months until next milestone

Study Start

First participant enrolled

August 5, 2025

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2027

Last Updated

March 31, 2026

Status Verified

March 1, 2026

Enrollment Period

1.5 years

First QC Date

March 5, 2025

Last Update Submit

March 26, 2026

Conditions

Keywords

Continous Glucose MonitoringCognitionGut-microbiota-brain axis

Outcome Measures

Primary Outcomes (7)

  • Glycemic variability

    Mean and standard deviation of glucose measures in mg/dL using a CGM 10 days.

    36 month

  • The percentage of time in glucose target range (glucose level 100mg/dl-125mg/dl)

    36 months

  • The glycaemic risk measured with the low blood glucose index (LBGI)

    Low blood glucose index (LBGI) is a parameter that quantifies the risk of glycaemic.

    36 months

  • The glycaemic variability measured with mean amplitude of glycaemic excursions (MAGE)

    measured in mg/dl

    36 months

  • Minutes light sleep

    Mean and standard deviation of minutes' light sleep measures by activity and sleep tracker device.

    36 months

  • Minutes deep sleep

    Mean and standard deviation of minutes' deep sleep measures by activity and sleep tracker device.

    36 months

  • Minutes rapid eye movement (REM)

    Mean and standard deviation of minutes REM measures by activity and sleep tracker device.

    36 months

Secondary Outcomes (43)

  • Audioverbal memory

    36 months

  • Effect on gut microbiota

    36 months

  • Visual memory

    36 months

  • Depressive symptomatology

    36 months

  • Impulsivity

    36 months

  • +38 more secondary outcomes

Study Arms (2)

OBESITY

With 2 subgroups * Man with obesity * Women with obesity

WITHOUT OBESITY

With 2 subgroups: * Man without obesity * Women without obesity

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

We will make use of the existing samples from the FATBANK cohort (a platform driven by CIBEROBN, managed by the IDIBGI Biobank, and part of the Spanish National Biobank Network). Participants in this cohort had previously signed informed consent to be contacted again. Therefore, the selected participants will be reappointed at the Endocrinology, Diabetes, and Nutrition Service (UDENTG) of the Dr. Josep Trueta Hospital.

You may qualify if:

  • Men and women \>20 years old.
  • Scheduled for surgical intervention to extract adipose tissue.
  • Signed informed consent for study participation.

You may not qualify if:

  • Non-obesity-related systemic diseases (cancer, severe kidney/liver disease).
  • Systemic diseases with intrinsic inflammation (rheumatoid arthritis, Crohn's disease, asthma, chronic infections (HIV/tuberculosis)) or any type of infectious disease.
  • Pregnant/breastfeeding women.
  • Persons under legal/administrative restrictions.
  • Those with infection symptoms in the past month.
  • Use of antibiotics/antifungals/antivirals (previous 3 months).
  • Chronic steroidal/anti-inflammatory drug use.
  • Major psychiatric history.
  • Excessive alcohol intake, acute or chronic (\>40g/day (women), \>80g/day (men)) or drug abuse.
  • Immunosuppressants treatment.
  • Participants with severe eating disorders.
  • Serum liver enzymes (GOT, GPT) above twice the upper limit of normal. Obvious signs or symptoms of liver disease, acute or chronic hepatitis.
  • History of iron balance disorders (e.g., genetic hemochromatosis, hemosiderosis from any cause, atransferrinemia, paroxysmal nocturnal hemoglobinuria).
  • Creatinine greater than 1.2 and glomerular filtration rate below 40.
  • Current treatment for malignant neoplasia, other than basal cell or squamous cell skin cancer.
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institut d'Investigació Biomèdica de Girona (IDIBGI)

Girona, Girona, 17007, Spain

RECRUITING

Related Publications (32)

  • Mayneris-Perxachs J, Arnoriaga-Rodriguez M, Garre-Olmo J, Puig J, Ramos R, Trelis M, Burokas A, Coll C, Zapata-Tona C, Pedraza S, Perez-Brocal V, Ramio L, Ricart W, Moya A, Jove M, Sol J, Portero-Otin M, Pamplona R, Maldonado R, Fernandez-Real JM. Presence of Blastocystis in gut microbiota is associated with cognitive traits and decreased executive function. ISME J. 2022 Sep;16(9):2181-2197. doi: 10.1038/s41396-022-01262-3. Epub 2022 Jun 21.

    PMID: 35729225BACKGROUND
  • Bier E. Drosophila, the golden bug, emerges as a tool for human genetics. Nat Rev Genet. 2005 Jan;6(1):9-23. doi: 10.1038/nrg1503.

    PMID: 15630418BACKGROUND
  • Douglas AE. The Drosophila model for microbiome research. Lab Anim (NY). 2018 Jun;47(6):157-164. doi: 10.1038/s41684-018-0065-0. Epub 2018 May 23.

    PMID: 29795158BACKGROUND
  • Quesada-Vazquez S, Castells-Nobau A, Latorre J, Oliveras-Canellas N, Puig-Parnau I, Tejera N, Tobajas Y, Baudin J, Hildebrand F, Beraza N, Burcelin R, Martinez-Gili L, Chilloux J, Dumas ME, Federici M, Hoyles L, Caimari A, Del Bas JM, Escote X, Fernandez-Real JM, Mayneris-Perxachs J. Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity. Cell Rep Med. 2023 Dec 19;4(12):101341. doi: 10.1016/j.xcrm.2023.101341.

    PMID: 38118419BACKGROUND
  • Mayneris-Perxachs J, Moreno-Navarrete JM, Ballanti M, Monteleone G, Alessandro Paoluzi O, Mingrone G, Lefebvre P, Staels B, Federici M, Puig J, Garre J, Ramos R, Fernandez-Real JM. Lipidomics and metabolomics signatures of SARS-CoV-2 mediators/receptors in peripheral leukocytes, jejunum and colon. Comput Struct Biotechnol J. 2021;19:6080-6089. doi: 10.1016/j.csbj.2021.11.007. Epub 2021 Nov 8.

    PMID: 34777716BACKGROUND
  • Lin H, Peddada SD. Analysis of compositions of microbiomes with bias correction. Nat Commun. 2020 Jul 14;11(1):3514. doi: 10.1038/s41467-020-17041-7.

    PMID: 32665548BACKGROUND
  • Albanese D, Donati C. Strain profiling and epidemiology of bacterial species from metagenomic sequencing. Nat Commun. 2017 Dec 22;8(1):2260. doi: 10.1038/s41467-017-02209-5.

    PMID: 29273717BACKGROUND
  • Zhao S, Li H, Han W, Chan W, Li L. Metabolomic Coverage of Chemical-Group-Submetabolome Analysis: Group Classification and Four-Channel Chemical Isotope Labeling LC-MS. Anal Chem. 2019 Sep 17;91(18):12108-12115. doi: 10.1021/acs.analchem.9b03431. Epub 2019 Sep 5.

    PMID: 31441644BACKGROUND
  • Arnoriaga-Rodriguez M, Mayneris-Perxachs J, Burokas A, Contreras-Rodriguez O, Blasco G, Coll C, Biarnes C, Miranda-Olivos R, Latorre J, Moreno-Navarrete JM, Castells-Nobau A, Sabater M, Palomo-Buitrago ME, Puig J, Pedraza S, Gich J, Perez-Brocal V, Ricart W, Moya A, Fernandez-Real X, Ramio-Torrenta L, Pamplona R, Sol J, Jove M, Portero-Otin M, Maldonado R, Fernandez-Real JM. Obesity Impairs Short-Term and Working Memory through Gut Microbial Metabolism of Aromatic Amino Acids. Cell Metab. 2020 Oct 6;32(4):548-560.e7. doi: 10.1016/j.cmet.2020.09.002.

    PMID: 33027674BACKGROUND
  • Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodriguez M, Garre-Olmo J, Puig J, Ramos R, Martinez-Hernandez F, Burokas A, Coll C, Moreno-Navarrete JM, Zapata-Tona C, Pedraza S, Perez-Brocal V, Ramio-Torrenta L, Ricart W, Moya A, Martinez-Garcia M, Maldonado R, Fernandez-Real JM. Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans. Cell Host Microbe. 2022 Mar 9;30(3):340-356.e8. doi: 10.1016/j.chom.2022.01.013. Epub 2022 Feb 16.

    PMID: 35176247BACKGROUND
  • Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodriguez M, Martin M, de la Vega-Correa L, Zapata C, Burokas A, Blasco G, Coll C, Escrichs A, Biarnes C, Moreno-Navarrete JM, Puig J, Garre-Olmo J, Ramos R, Pedraza S, Brugada R, Vilanova JC, Serena J, Gich J, Ramio-Torrenta L, Perez-Brocal V, Moya A, Pamplona R, Sol J, Jove M, Ricart W, Portero-Otin M, Deco G, Maldonado R, Fernandez-Real JM. Microbiota alterations in proline metabolism impact depression. Cell Metab. 2022 May 3;34(5):681-701.e10. doi: 10.1016/j.cmet.2022.04.001.

    PMID: 35508109BACKGROUND
  • Oliveras-Canellas N, Castells-Nobau A, de la Vega-Correa L, Latorre-Luque J, Motger-Alberti A, Arnoriaga-Rodriguez M, Garre-Olmo J, Zapata-Tona C, Coll-Martinez C, Ramio-Torrenta L, Moreno-Navarrete JM, Puig J, Villarroya F, Ramos R, Casado-Anguera V, Martin-Garcia E, Maldonado R, Mayneris-Perxachs J, Fernandez-Real JM. Adipose tissue coregulates cognitive function. Sci Adv. 2023 Aug 11;9(32):eadg4017. doi: 10.1126/sciadv.adg4017. Epub 2023 Aug 11.

    PMID: 37566655BACKGROUND
  • Xia D, Kelleher RJ 3rd, Shen J. Loss of Abeta43 Production Caused by Presenilin-1 Mutations in the Knockin Mouse Brain. Neuron. 2016 Apr 20;90(2):417-22. doi: 10.1016/j.neuron.2016.03.009.

    PMID: 27100200BACKGROUND
  • Wechsler, D. WAIS IV: Escala de Inteligencia de Wechsler para Adultos-IV. Madrid: TEA. 2012

    BACKGROUND
  • Guo DH, Yamamoto M, Hernandez CM, Khodadadi H, Baban B, Stranahan AM. Beige adipocytes mediate the neuroprotective and anti-inflammatory effects of subcutaneous fat in obese mice. Nat Commun. 2021 Jul 30;12(1):4623. doi: 10.1038/s41467-021-24540-8.

    PMID: 34330904BACKGROUND
  • Guo DH, Yamamoto M, Hernandez CM, Khodadadi H, Baban B, Stranahan AM. Visceral adipose NLRP3 impairs cognition in obesity via IL-1R1 on CX3CR1+ cells. J Clin Invest. 2020 Apr 1;130(4):1961-1976. doi: 10.1172/JCI126078.

    PMID: 31935195BACKGROUND
  • Sodhi K, Pratt R, Wang X, Lakhani HV, Pillai SS, Zehra M, Wang J, Grover L, Henderson B, Denvir J, Liu J, Pierre S, Nelson T, Shapiro JI. Role of adipocyte Na,K-ATPase oxidant amplification loop in cognitive decline and neurodegeneration. iScience. 2021 Oct 12;24(11):103262. doi: 10.1016/j.isci.2021.103262. eCollection 2021 Nov 19.

    PMID: 34755095BACKGROUND
  • Morrison SF, Nakamura K. Central Mechanisms for Thermoregulation. Annu Rev Physiol. 2019 Feb 10;81:285-308. doi: 10.1146/annurev-physiol-020518-114546. Epub 2018 Sep 26.

    PMID: 30256726BACKGROUND
  • Cardoso F, Klein Wolterink RGJ, Godinho-Silva C, Domingues RG, Ribeiro H, da Silva JA, Mahu I, Domingos AI, Veiga-Fernandes H. Neuro-mesenchymal units control ILC2 and obesity via a brain-adipose circuit. Nature. 2021 Sep;597(7876):410-414. doi: 10.1038/s41586-021-03830-7. Epub 2021 Aug 18.

    PMID: 34408322BACKGROUND
  • Zeng W, Pirzgalska RM, Pereira MM, Kubasova N, Barateiro A, Seixas E, Lu YH, Kozlova A, Voss H, Martins GG, Friedman JM, Domingos AI. Sympathetic neuro-adipose connections mediate leptin-driven lipolysis. Cell. 2015 Sep 24;163(1):84-94. doi: 10.1016/j.cell.2015.08.055.

    PMID: 26406372BACKGROUND
  • Farruggia MC, Small DM. Effects of adiposity and metabolic dysfunction on cognition: A review. Physiol Behav. 2019 Sep 1;208:112578. doi: 10.1016/j.physbeh.2019.112578. Epub 2019 Jun 11.

    PMID: 31194997BACKGROUND
  • Gardener H, Caunca M, Dong C, Cheung YK, Rundek T, Elkind MSV, Wright CB, Sacco RL. Obesity Measures in Relation to Cognition in the Northern Manhattan Study. J Alzheimers Dis. 2020;78(4):1653-1660. doi: 10.3233/JAD-201071.

    PMID: 33164939BACKGROUND
  • Dahl AK, Hassing LB, Fransson EI, Gatz M, Reynolds CA, Pedersen NL. Body mass index across midlife and cognitive change in late life. Int J Obes (Lond). 2013 Feb;37(2):296-302. doi: 10.1038/ijo.2012.37. Epub 2012 Mar 27.

    PMID: 22450854BACKGROUND
  • Tang X, Zhao W, Lu M, Zhang X, Zhang P, Xin Z, Sun R, Tian W, Cardoso MA, Yang J, Simo R, Zhou JB, Stehouwer CDA. Relationship between Central Obesity and the incidence of Cognitive Impairment and Dementia from Cohort Studies Involving 5,060,687 Participants. Neurosci Biobehav Rev. 2021 Nov;130:301-313. doi: 10.1016/j.neubiorev.2021.08.028. Epub 2021 Aug 28.

    PMID: 34464646BACKGROUND
  • Qu Y, Hu HY, Ou YN, Shen XN, Xu W, Wang ZT, Dong Q, Tan L, Yu JT. Association of body mass index with risk of cognitive impairment and dementia: A systematic review and meta-analysis of prospective studies. Neurosci Biobehav Rev. 2020 Aug;115:189-198. doi: 10.1016/j.neubiorev.2020.05.012. Epub 2020 May 30.

    PMID: 32479774BACKGROUND
  • Endle H, Horta G, Stutz B, Muthuraman M, Tegeder I, Schreiber Y, Snodgrass IF, Gurke R, Liu ZW, Sestan-Pesa M, Radyushkin K, Streu N, Fan W, Baumgart J, Li Y, Kloss F, Groppa S, Opel N, Dannlowski U, Grabe HJ, Zipp F, Racz B, Horvath TL, Nitsch R, Vogt J. AgRP neurons control feeding behaviour at cortical synapses via peripherally derived lysophospholipids. Nat Metab. 2022 Jun;4(6):683-692. doi: 10.1038/s42255-022-00589-7. Epub 2022 Jun 27.

    PMID: 35760867BACKGROUND
  • Suarez AN, Hsu TM, Liu CM, Noble EE, Cortella AM, Nakamoto EM, Hahn JD, de Lartigue G, Kanoski SE. Gut vagal sensory signaling regulates hippocampus function through multi-order pathways. Nat Commun. 2018 Jun 5;9(1):2181. doi: 10.1038/s41467-018-04639-1.

    PMID: 29872139BACKGROUND
  • Minhas PS, Latif-Hernandez A, McReynolds MR, Durairaj AS, Wang Q, Rubin A, Joshi AU, He JQ, Gauba E, Liu L, Wang C, Linde M, Sugiura Y, Moon PK, Majeti R, Suematsu M, Mochly-Rosen D, Weissman IL, Longo FM, Rabinowitz JD, Andreasson KI. Restoring metabolism of myeloid cells reverses cognitive decline in ageing. Nature. 2021 Feb;590(7844):122-128. doi: 10.1038/s41586-020-03160-0. Epub 2021 Jan 20.

    PMID: 33473210BACKGROUND
  • Coin-Araguez L, Pavon FJ, Contreras A, Gentile AM, Lhamyani S, De Diego-Otero Y, Casado Y, Oliva Olivera W, Olveira G, Tinahones FJ, Perez Costillas L, El Bekay R. Inflammatory gene expression in adipose tissue according to diagnosis of anxiety and mood disorders in obese and non-obese subjects. Sci Rep. 2018 Nov 30;8(1):17518. doi: 10.1038/s41598-018-35759-9.

    PMID: 30504920BACKGROUND
  • Das SK, Ma L, Sharma NK. Adipose tissue gene expression and metabolic health of obese adults. Int J Obes (Lond). 2015 May;39(5):869-73. doi: 10.1038/ijo.2014.210. Epub 2014 Dec 18.

    PMID: 25520251BACKGROUND
  • Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006 Jun;55(6):1537-45. doi: 10.2337/db06-0263.

    PMID: 16731815BACKGROUND
  • Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, Beguinot F, Miele C. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019 May 13;20(9):2358. doi: 10.3390/ijms20092358.

    PMID: 31085992BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

saliva, stool, blood and urine

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • José Manuel Fernández-Real, M.D., Ph.D.

    Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta

    PRINCIPAL INVESTIGATOR

Central Study Contacts

José Manuel Fernández-Real, M.D., Ph.D.

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
1 Month
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator, clinical professor, section chief of Endocrinology and Nutrition Department of Josep Trueta University Hospital

Study Record Dates

First Submitted

March 5, 2025

First Posted

March 11, 2025

Study Start

August 5, 2025

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

January 31, 2027

Last Updated

March 31, 2026

Record last verified: 2026-03

Locations